Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 23, 2008

View Archived Issues

Novel lysosomal enzyme replacement therapy for MPS that crosses the BBB

Studies find little benefit of add-on lamotrigine in refractory schizophrenia patients

Argyll successfully completes first phase of formal proof of concept trial for SF-1019

Novel analgesic agents imparted in recent Vertex and Merck Frosst patents

New therapeutic agents for cardiovascular disorders reported in recent patents

Positive clinical trial results for epilepsy drug rufinamide in mood disorders

Recent patent discloses new therapeutic agents for liver diseases

Bionomics presents R&D update

Amarin provides pipeline update

Novel SMN2 promoter activator by deCODE may be useful in SMA

Genmab reaches two milestones in ofatumumab collaboration with GSK

Threshold provides update on several glufosfamide clinical trials

VIRxSYS signs research agreement with National Heart, Lung, and Blood Institute

Diamyd reports 30-month results from phase IIb study of diabetes vaccine Diamyd

LifeCycle reports interim results from phase II trial of LCP-Tacro in liver transplants

FDA approves Celsion's SPA application for phase III liver cancer trial of ThermoDox

StemCells reports death of patient in phase I clinical trial of HuCNS-SC for NCL

Tripep and Kringle Pharma apply for permission to initiate phase II study of ChronSeal

FDA has not yet made decision on Cardiome's and Astellas' NDA for Kynapid

Trophos completes enrollment of first 90 patients in phase IIa clinical trial of TRO-19622

Serenex and CHDI enter agreement to evaluate Hsp90 inhibitors for Huntington's disease

Synta initiates second phase I clinical trial of novel Hsp90 inhibitor STA-9090 in solid tumors

Positive phase III preliminary results reported for prolonged-release octreotide

Abraxis receives E.U. approval to market Abraxane for metastatic breast cancer

Additional indication for Astellas' Mycamine gets FDA approval

Fast track designation for Sabril in cocaine and methamphetamine dependence treatment

FDA accepts oral fludarabine NDA for review

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...